L. Szczechowski

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

A. Traboulsee, B. Weinshenker, H. Garren, 2020, The Lancet Neurology.

Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.

M. Gorny, S. Ochudło, L. Szczechowski, 1989, Acta medica Polona.

Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis – whom, when and how

G. Helbig, L. Szczechowski, S. Kyrcz‐Krzemień, 2016, The International journal of neuroscience.

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

J. Statland, M. Pasnoor, J. Verschuuren, 2021, The Lancet Neurology.

Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.

A. Haycox, G. Klingelschmitt, H. von Büdingen, 2021, Multiple Sclerosis and Related Disorders.

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Adam L. Comer, Robert G. Miller, S. Demeret, 2023, The Lancet Neurology.

Frequency of mutations in PRKN, PINK1, and DJ1 in Patients With Early-Onset Parkinson Disease from neighboring countries in Central Europe.

M. Barcikowska, J. Siuda, G. Opala, 2021, Parkinsonism & Related Disorders.

METHODS OF RESUSCITATION.

P. Jałowiecki, L. Szczechowski, E. Karpel, 1914, Science.